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This study assesses whether oxidative stress, using oxidized LDL (ox-LDL) as proxy, is 
associated with metabolic syndrome (MS), whether ox-LDL mediates the association 
between central obesity and MS, and whether insulin resistance mediates the association 
between ox-LDL and MS. We examined baseline data from 3987 non-diabetic subjects in the 
Progression of Early Subclinical Atherosclerosis (PESA) Study. For the 2nd, 3rd, and 4th ox-
LDL quartiles versus the 1st, the odds ratios (95% confidence interval) for MS were 0.84 
(0.52, 1.36), 1.47 (0.95, 2.32), and 2.57 (1.66, 4.04) (p<0.001 for trend) once adjusted for 
age, sex, smoking, LDL-cholesterol, body mass index, waist circumference, and HOMA-IR. 
Results showing the same trend were found for all MS components except glucose 
concentration. Ox-LDL mediated 13.9 % of the association of waist circumference with 
triglycerides and only 1-3% of the association with HDL-cholesterol, blood pressure, and 
insulin concentration. HOMA-IR did not mediate the association between ox-LDL and MS 
components. In this study, higher ox-LDL concentrations were associated with MS and its 
components independently of central obesity and insulin resistance. Ox-LDL may reflect core 
mechanisms through which MS components develop and progress in parallel with insulin 
resistance and could be a clinically relevant predictor of MS development. 
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Increased oxidative stress is the consequence of an imbalance between oxidant and 
antioxidant biological agents and can result in damage to biomolecules, including proteins, 
nucleic acids, and lipids. Some of these damaged biomolecules have been used as oxidative 
stress biomarkers, such as oxidized-low density lipoproteins (ox-LDL)(1), that can be 
measured from a regular blood draw. 
Oxidative stress is suspected to be involved in the pathophysiology of several chronic 
diseases(2,3) and has been linked to metabolic syndrome (MS), a cluster of risk factors for 
cardiovascular disease that includes central obesity, high blood pressure, high fasting glucose, 
and dyslipidemia(4–7). A common hallmark of MS-associated dyslipidemia is elevation of 
small and dense low-density lipoprotein (LDL) particles, which are easily oxidized(8). Also, 
high ox-LDL levels are associated with insulin resistance(9), which is tightly linked to the 
pathogenesis of MS(10). Insulin resistance may arise from oxidative-stress-mediated 
activation of kinase signaling cascades that phosphorylate insulin receptors, leading to 
impaired insulin action(11); but it is also related to the correlation between plasma glucose 
and LDL susceptibility to oxidation(12). Indeed, high glucose concentrations might even 
induce LDL oxidation(13,14). In addition, obesity is the main origin of MS and it has been 
involved with induction of oxidative stress(15), which in turn may contribute to the 
development of MS(16). 
However, no previous study has analyzed with detail which elements mediate the 
associations between obesity, oxidative stress, insulin resistance, and MS in humans. Using 
data from the Progression of Early Subclinical Atherosclerosis (PESA) study(17), which is a 
carefully phenotyped sample with size big enough to address subtle associations, this study 
aims to assess 1) whether oxidative stress, using ox-LDL as a proxy, is associated with MS, 
2) whether ox-LDL mediates the association between central obesity and MS, and 3) whether 
insulin resistance mediates the association between ox-LDL and MS (Supplementary Figure 
1). 
RESEARCH DESIGN AND METHODS 
Study design and population 
We used baseline data from PESA(17), a prospective cohort study aimed to evaluate 
traditional and novel risk factors and atherosclerosis in the carotid, aortic, coronary and 
iliofemoral territories using accessible noninvasive imaging techniques(18) in asymptomatic 
male and female employees (40-54 years old) of the Banco Santander in Madrid (Spain) who 
were free of clinical atherosclerosis. All participants were recruited between 2010 and 2013. 
The PESA study was approved by the Ethics Committee of the Instituto de Salud Carlos III in 
Madrid, the study protocol was conducted according to the guidelines of The Helsinki 
Declaration, and all participants gave written informed consent. 
From an initial sample of 4117 participants, we excluded 82 with diabetes, 2 with 
missing ox-LDL data, and 46 with no recorded smoking status. Data was complete for all 
other relevant variables. The final analytical sample thus included 3987 individuals. 
Data collection 
Data were obtained from structured clinical interviews and questionnaires, a physical 
exam, and a fasting blood sample. With the patient standing, waist circumference was 
measured at a midpoint plane between the iliac crest and the costal border. Weight was 
measured without shoes and outdoor clothes to the nearest 0.1 kg. Height was measured to 
the nearest 0.1 cm, again without shoes and with participants standing upright with their back 
to the stadiometer. Body mass index (BMI) was calculated as weight divided by height 
squared (kg/m2); overweight was defined as BMI between 25 and 30, and obesity as 
BMI≥30(19). Blood pressure was calculated as the mean of three consecutive measurements 
made with an automatic oscillometric OMRON HEM-907 sphygmomanometer (OMRON 
Healthcare Co. Ltd., Kyoto, Japan), which has been validated according to international 
protocols(20); participants were seated for 5 minutes before the measurements were made, 
and blood pressure readings were made at 1-minute intervals. All procedures were ISO-9001 
certified. 
Laboratory measurements 
Peripheral venous blood was collected after an 8-hour fast. A monoclonal antibody 
4E6–based competition ELISA (Mercodia AB, Sweden) was used for measuring plasma 
levels of ox-LDL. Monoclonal antibody 4E6 is directed against a conformational epitope in 
the apoB-100 moiety of LDL that is generated as a consequence of substitution of lysine 
residues of apoB-100 with aldehydes. Whole blood HbA1c was measured by reverse-phase 
cationic exchange chromatography and double wavelength colorimetric quantification 
(BIORAD D-10, D-10™ Hemoglobin Testing System). Triglycerides, total cholesterol, 
HDL-cholesterol, and glucose were measured in serum with spectrophotometric assays in the 
Architect-Ci8200 analyzer, using the manufacturer’s kits (Instrumentation Laboratory). 
Insulin was determined in the same analyzer by chemiluminescence immunoassay. Low-
density lipoprotein cholesterol (LDL-cholesterol) was calculated from the Friedewald 
equation. 
Metabolic syndrome and insulin resistance 
According to the 2009 harmonizing definition(21), MS was diagnosed when 
participants met at least 3 of the following 5 criteria: high waist circumference (≥102 cm in 
men and ≥88 cm in women), high triglycerides (≥1.7 mmol/L, i.e. ≥150 mg/dL), low high-
density lipoprotein cholesterol (HDL-cholesterol) (<1.0 mmol/L, i.e. <40 mg/dL, in men and 
<1.3 mmol/L, i.e. <50 mg/dL in women), high blood pressure (≥ 130/85 mmHg or treatment 
with antihypertensive medication), and high fasting glucose (≥5.6 mmol/L, i.e. ≥100 mg/dL, 
or drug treatment for elevated glucose). 
HOMA-IR (Homeostatic model assessment - Insulin Resistance) was calculated as 
glucose (mg/dL) multiplied by insulin (µU/mL) and divided by 405(22). Insulin resistance 
was defined as HOMA-IR ≥2.6(23). 
Statistical analysis 
Adjusted mean differences in metabolic variables across ox-LDL quartiles were 
calculated using linear regression analysis. Odds ratios (OR) and their 95% confidence 
interval (CI) were estimated with generalized linear models to quantify the association of 
quartiles of ox-LDL with the presence of MS, its components, insulin resistance, and 
metabolic clusters. Analyses used the first ox-LDL quartile as the reference group. 
A basic model was adjusted for age (continuous), sex, smoking status, and LDL-
cholesterol (continuous); we decided to include LDL-cholesterol in the basic model of 
adjustment because it is strongly associated with ox-LDL. The full model was adjusted for 
the variables in the basic model plus HOMA-IR (log-transformed), BMI (continuous), and 
waist circumference (continuous). Models including ox-LDL as a continuous variable were 
used to assess linear trend and to perform a bootstrapped mediation analysis. 
As the full model included waist circumference (one of the variables used in the MS 
definition), we also evaluated the association of ox-LDL with clusters of non-anthropometric 
MS components: ≥2 or ≥3 criteria for MS other than high waist circumference. 
Mediation analysis was used to analyze the extent to which ox-LDL explains the 
association of central obesity (measured by waist circumference) with MS components and 
the extent to which HOMA-IR mediates the effect of ox-LDL on MS component values. The 
average direct effect, the average causal mediation effect, and the proportion of effect 
mediated with respect to the total effect were estimated by means of non-parametric 
bootstrapping with 1000 resamples and percentile-based confidence intervals(24). 
Differences were considered statistically significant at p < 0.05. Statistical analyses 
were performed using R statistical software (version 3.1)(25) and the mediation package(24). 
RESULTS 
The PESA participants included in these analyses (n=3987) had a mean age 45.7 (4.2) 
y, and 62.4% were men. In total, 9.9% of participants had MS, 8.2% had insulin resistance, 
44.3% were overweight, and 14.0% were obese (Table 1). The mean ox-LDL concentration 
was 51.8 (17.0) U/L. Almost half the individuals with MS were insulin resistant, compared 
with less than 5% of those who were classified as non-MS (Table 1). 
After adjusting for age, sex, smoking, and LDL-cholesterol, ox-LDL was associated 
with higher BMI and waist circumference, triglycerides, total cholesterol, blood pressure, 
insulin, HOMA-IR, and HbA1c, and with lower HDL-cholesterol. Moreover, these 
associations remained significant after additionally adjusting for HOMA-IR, BMI, and waist 
circumference (Table 2). After adjustment for waist circumference, there was no positive 
association between ox-LDL and BMI (Table 2 and Supplementary Table 1, models 4 and 6). 
Similarly, after adjusting for the anthropometric variables, the association between ox-LDL 
and HOMA-IR substantially decreased, even becoming non-significant (Table 2 and 
Supplementary Table 1, models 3, 4 and 7). 
The frequency of MS and its components increased across ox-LDL quartiles. With the 
exception of high fasting glucose, associations with MS components were independent of 
HOMA-IR and anthropometric measurements (Table 3, full model). The MS component with 
the strongest association was high triglycerides concentration. Ox-LDL was significantly 
associated with insulin resistance independently of BMI and waist circumference. The ORs 
(95% confidence interval) for MS in the 2nd, 3rd, and 4th ox-LDL quartile versus the 1st were 
0.84 (0.52, 1.36), 1.47 (0.95, 2.32), and 2.57 (1.66, 4.04) independently of HOMA-IR, BMI, 
and waist circumference (Table 3, full model, p<0.001 for trend). The 2nd, 3rd, and 4th versus 
1st ox-LDL quartile ORs for the cluster of three non-anthropometric MS components were 
1.52 (0.76, 3.13), 2.55 (1.36, 4.99), and 5.27 (2.88, 10.20) also independently of insulin 
sensitivity and anthropometry (Table 3, full model, p<0.001 for trend). 
Analysis of ox-LDL mediation on the association between waist circumference and 
MS- related variables showed that ox-LDL mediated 13.9 % of the association between waist 
circumference and triglycerides concentration and from 1% to 3% of the association of waist 
circumference with HDL-cholesterol, blood pressure, and insulin (Table 4). 
HOMA-IR did not mediate any of the associations between ox-LDL and MS 
(Supplementary Table 2); this finding is consistent with the lack of association between ox-
LDL and HOMA-IR after adjustment for anthropometric variables. In contrast, most of the 
associations of waist circumference with the MS components were partly mediated by 
increased HOMA-IR, particularly for triglycerides and blood pressure (Supplementary Table 
3). We also observed that higher LDL-cholesterol was only weakly associated with MS and 
that the association disappeared, and even reversed, once adjusted for ox-LDL 
(Supplementary Table 4). As a sensitivity analysis, we further adjusted the estimations of the 
association of ox-LDL with each MS criterion for the rest of MS criteria, and these 
associations still held for high waist circumference, high triglycerides, and high blood 
pressure (Supplementary Table 5). 
DISCUSSION 
In this study of 3987 non-diabetic PESA participants, ox-LDL was strongly associated 
with MS and its components independently of central obesity and insulin resistance. In spite 
of the association between ox-LDL and waist circumference, the relation between central 
obesity and MS components was not substantially mediated by ox-LDL. Additionally, despite 
it was proposed that oxidative stress may act as a cause of insulin resistance(26–28), our 
observations suggest that the association of ox-LDL with MS is not mediated by insulin 
resistance. Our analysis shows that ox-LDL variation, presumably caused by factors other 
than central obesity, is associated with changes in metabolic parameters. Thus, our findings 
suggest that ox-LDL could be a useful early predictive marker of cardiometabolic 
abnormalities before the appearance of insulin resistance. 
Several studies have described an association between ox-LDL and MS. Holvoet et 
al.(29) reported that elderly individuals with MS were more likely to have high circulating 
levels of ox-LDL. Also, Lapointe et al.(30) noted that higher ox-LDL concentrations were 
associated with MS in postmenopausal women. Moreover, Ueba et al.(31) described that MS, 
defined according to Japanese criteria, was twice as likely among individuals with higher ox-
LDL levels. Furthermore, in the Coronary Artery Risk Development in Young Adults study 
(CARDIA), a higher ox-LDL was associated with an increased incidence of MS(6). In fact, 
superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), natural antioxidant 
defenses, are reduced in MS(32), probably consumed by increased oxidative stress. Animal 
studies show that this occurs in diet-induced MS as a consequence of NADPH oxidase over-
activation(33). Therefore, oxidative stress was considered to play a role in the initiation and 
progression of metabolic disorders(2). Nonetheless, this role has not been previously 
addressed with mediation analysis methods in human studies, as our analysis does. 
Interestingly, oxidative stress has also been contemplated as a consequence of chronic 
hyperglycemia and obesity(2,34). In these disorders, peroxidation species are believed to 
promote the development of MS(4,6,7,35,36), and oxidative stress was proposed as a 
mediator between obesity and MS(16). One mechanism for such process might be oxidative 
stress-induced insulin resistance, which is considered a key disorder in the progression to 
MS(11,37). In the intersection between obesity, clinical diabetes, and oxidative stress it is 
difficult to determine which of their pathways acts first(2). In our sample of non-diabetic 
individuals, with a mean BMI of 26.1 kg/m2 and only 14% of participants obese, we were 
able to address early steps in MS development. In this population, ox-LDL was associated 
with MS independently of central obesity and insulin resistance, and was additionally 
associated to the lipid and blood pressure MS components, as well as their clustering. 
Adiposity seems to play an important role in oxidative stress(38–42). Adipose tissue 
is metabolically active, and expresses inflammatory cytokines; in turn, inflammation 
increases reactive oxygen species(43), which dysregulate adipocytokines and might thus be 
involved in the pathogenesis of MS, as demonstrated in animal and human studies(2,44,45). 
Nonetheless, in the early stages of the MS that are the focus of the present study, increased 
ox-LDL linked to elevated waist circumference might not be an essential intermediate 
pathway connecting obesity and MS. Indeed, ox-LDL only explained 15% of the association 
of waist circumference with triglycerides, and very small proportions of the association with 
other MS components. 
Oxidative stress activates kinase signaling cascades that impair insulin function, 
through modification and modulation of the insulin receptor and the insulin receptor 
substrate(11,27,46). This could be considered a compensatory mechanism to protect the cells 
from further increasing oxidation by limiting substrate intake(26). Oxidative stress also 
inhibits insulin action by triggering signals leading to adipogenesis (adipocyte hypertrophy 
and hyperplasia) and inflammation(47). Insulin resistance is a core driver of MS(10), 
providing a plausible pathway that would explain how MS may be in part a consequence of 
oxidative stress. However, our data show that ox-LDL is associated with the MS 
independently of insulin resistance, which implies that the association does not occur through 
insulin resistance, at least in the early stages of the MS development. Our findings thus 
suggest that ox-LDL is directly associated with the development of cardiometabolic risk 
factors and their clustering (MS), initially acting in parallel with insulin resistance. 
A possible interpretation of our findings is that the main pathophysiological change 
triggering MS is the shift in the metabolites used to produce energy(10), leading to lipid and 
hemodynamic disorders, inflammation, and atherosclerosis, with oxidative stress and insulin 
resistance (leading to diabetes) appearing as secondary consequences. Preferential use of fatty 
acids in oxidative phosphorylation produces higher levels of reactive oxygen species than 
oxidation of carbohydrates. Fatty-acid oxidation requires a large amount of oxygen that, in 
conditions of relative hypoxia due to decreased blood supply, could aggravate the 
situation(48–51): hypoxia favors tissue damage, macrophage infiltration, and increased 
adipocytokine production, ultimately increasing pro-inflammatory mediators, C-reactive 
protein, and plasminogen activator inhibitor-1. Triglycerides carried in lipoproteins rise in 
contexts of energy surplus. Additionally to energy substrate shift, lipoprotein lipase and 
hepatic triglyceride lipase metabolize the particles to an end form of small and dense LDL, 
which is particularly susceptible to oxidation. Consequently, the association between ox-LDL 
and triglycerides, which is the strongest that we found among the MS components, may be 
partly due to their common participation in lipids pathways, beyond triglycerides 
participation in the MS. In parallel, free fatty acids, which are highly available in situations 
leading to MS, induce insulin resistance by inhibiting insulin-mediated glucose uptake. In this 
interpretation, oxidative stress and insulin resistance would be independent markers of the 
metabolic shift taking place. Consequently, ox-LDL could be used as a telltale of the early 
stages of cardiometabolic risk, even before the appearance of insulin resistance. Ox-LDL also 
contributes to the development of atherosclerosis and cardiovascular 
diseases(52,53,16,54,55), which are associated with MS. 
This study was based on a sample of well-characterized and deeply phenotyped 
individuals using state-of-the-art quality control procedures. A sample size of almost 4000 
individuals and modern statistical methods have allowed describing some biological 
processes which mediate the clustering of the risk factors in MS and have raised doubt about 
the relevance of some previously suggested paths. Nonetheless, the study design is cross-
sectional, which limits the ability to establish that the link between oxidative stress and MS is 
causal. In addition, ox-LDL is one of the markers of oxidative stress and studies using a 
different marker might show complementary aspects of the process that links obesity and MS. 
Besides, regressions were adjusted for the main potential confounders, but it is possible that 
some residual confounding still exist due to unmeasured or unknown confounders. Analyses 
were adjusted for HOMA-IR as a continuous variable, which reflects a range of insulin 
sensitivities among non-diabetic individuals. At the early stages of metabolic disorders 
studied in our work, HOMA-IR was significantly associated with other metabolic variables 
but it did not mediate nor confound the observed associations. However, among diabetic 
patients, HOMA-IR reaches higher values and our results should be confirmed by future 
research. 
In conclusion, this study shows that higher ox-LDL concentrations are associated with 
MS and its components independently of central obesity and insulin resistance. Levels of ox-
LDL may thus reflect core mechanisms through which MS components develop and progress 
in parallel with insulin resistance and could be an early sign of MS development. 
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Male gender 62.4 [2488] 85.5 [336] 59.9 [2152] <0.001 
Age, y 45.7 (4.2) 47.6 (4.1) 45.5 (4.2) <0.001 
BMI, kg/m2 26.1 (3.8) 30.9 (3.5) 25.5 (3.4) <0.001 
Waist circumference, cm 89.1 (11.9) 104.5 (9.3) 87.4 (10.9) <0.001 
Triglycerides, mg/dL 93.4 (54.5) 157.4 (79.7) 86.4 (45.9) <0.001 
HDL-c, mg/dL 49.2 (12.2) 38.5 (7.3) 50.4 (12.0) <0.001 
Total cholesterol, mg/dL 200.7 (33.0) 209.8 (36.1) 199.7 (32.5) <0.001 
LDL-c, mg/dL 132.6 (29.6) 139.6 (31.4) 131.9 (29.3) <0.001 
Systolic blood pressure, mmHg 116.0 (12.4) 129.1 (13.0) 114.6 (11.5) <0.001 
Diastolic blood pressure, mmHg 72.4 (9.4) 82.7 (9.4) 71.2 (8.7) <0.001 
Fasting glucose, mg/dL 89.4 (8.7) 99.7 (9.1) 88.3 (7.9) <0.001 
Insulin, pmol/L 5.9 (3.5) 10.9 (4.9) 5.4 (2.9) <0.001 
HOMA-IR 1.3 (0.9) 2.7 (1.3) 1.2 (0.7) <0.001 
Hemoglobin A1c, % 5.4 (0.4) 5.6 (0.4) 5.4 (0.4) <0.001 
Ox-LDL, U/L 51.8 (17.0) 61.4 (19.5) 50.7 (16.3) <0.001 
Insulin resistance 8.2 [328] 44.5 [175] 4.3 [153] <0.001 
Obesity 14.0 [560] 56.2 [221] 9.4 [339] <0.001 
Overweight 44.3 [1765] 39.4 [155] 44.8 [1610] 0.048 
Smoking 28.2 [1123] 30.5 [120] 27.9 [1003] 0.298 
Data are presented as mean (standard deviation) or percentage [count]. 
BMI: Body Mass Index 
HDL-c: High-Density Lipoprotein Cholesterol 
LDL-c: Low-Density Lipoprotein Cholesterol 
HOMA-IR: Homeostatic Model Assessment—Insulin Resistance. 
Ox-LDL: Oxidized Low-Density Lipoprotein 
Mean hemoglobin A1c was 36 mmol/mol for the whole sample and those without metabolic 




Table 2. Mean values and adjusted differences (95% confidence interval) in metabolic 
syndrome-related parameters for comparison of the three highest ox-LDL quartiles with the 
first quartile 
 Quartiles of ox-LDL, U/L  
 [lowest,39.9] (39.9,49.4] (49.4,60.8] (60.8,highest] p trend 
N 997 997 996 997  
Mean ox-LDL, U/L 33.06 44.72 54.69 74.64  
Body mass index, kg/m2 24.93 25.58 26.41 27.37  
Basic model 0.00 0.23 0.61 1.03 <0.001 
 (Reference) (-0.07,0.53) (0.29,0.93) (0.68,1.39)  
Full model * 0.00 -0.02 -0.04 -0.20 0.02 
 (Reference) (-0.17,0.14) (-0.20,0.13) (-0.38,-0.02)  
Waist circumference, cm 84.72 87.15 90.20 94.20  
Basic model 0.00 0.86 2.12 3.91 <0.001 
 (Reference) (0.04,1.68) (1.25,2.99) (2.94,4.87)  
Full model * 0.00 0.42 0.76 1.43 <0.001 
 (Reference) (0.01,0.82) (0.33,1.19) (0.95,1.91)  
Triglycerides, mg/dL 71.87 82.64 95.22 123.97  
Basic model 0.00 8.41 17.48 42.47 <0.001 
 (Reference) (4.06,12.76) (12.87,22.08) (37.36,47.59)  
Full model 0.00 8.99 16.47 38.20 <0.001 
 (Reference) (4.91,13.07) (12.14,20.80) (33.37,43.03)  
HDL-cholesterol, mg/dL 52.17 50.46 48.74 45.56  
Basic model 0.00 -1.08 -1.78 -3.75 <0.001 
 (Reference) (-2.04,-0.13) (-2.80,-0.77) (-4.88,-2.63)  
Full model 0.00 -1.04 -1.31 -2.55 <0.001 
 (Reference) (-1.94,-0.13) (-2.28,-0.35) (-3.62,-1.47)  
Total cholesterol, mg/dL 178.75 191.46 206.37 226.16  
Basic model 0.00 0.59 1.71 4.75 <0.001 
 (Reference) (-0.51,1.70) (0.54,2.89) (3.44,6.05)  
Full model 0.00 0.76 1.98 5.10 <0.001 
 (Reference) (-0.35,1.86) (0.80,3.15) (3.79,6.41)  
LDL-cholesterol, mg/dL 112.05 124.34 138.44 155.65  
Basic model * 0.00 11.64 25.18 41.83 <0.001 
 (Reference) (9.48,13.81) (22.99,27.37) (39.59,44.06)  
Full model * 0.00 11.65 24.84 40.93 <0.001 
 (Reference) (9.49,13.81) (22.65,27.03) (38.67,43.19)  
Systolic blood pressure, mmHg 112.80 114.50 117.16 119.72  
Basic model 0.00 0.40 1.72 2.57 <0.001 
 (Reference) (-0.56,1.36) (0.70,2.74) (1.45,3.70)  
Full model 0.00 0.27 1.20 1.50 <0.001 
 (Reference) (-0.64,1.19) (0.23,2.17) (0.41,2.58)  
Diastolic blood pressure, mmHg 69.95 71.25 73.15 75.09  
Basic model 0.00 0.37 1.39 2.27 <0.001 
 (Reference) (-0.40,1.15) (0.57,2.21) (1.36,3.18)  
Full model 0.00 0.22 0.81 1.08 0.001 
 (Reference) (-0.49,0.93) (0.05,1.57) (0.23,1.92)  
Fasting glucose, mg/dL 87.94 88.47 90.10 91.28  
Basic model 0.00 -0.42 0.22 0.25 0.06 
 (Reference) (-1.13,0.29) (-0.52,0.97) (-0.58,1.08)  
Full model 0.00 -0.23 0.06 -0.65 0.27 
 (Reference) (-0.84,0.37) (-0.58,0.71) (-1.37,0.06)  
Insulin, pmol/L 5.26 5.39 5.99 7.15  
Basic model 0.00 -0.14 0.18 1.00 <0.001 
 (Reference) (-0.44,0.17) (-0.14,0.50) (0.64,1.35)  
Full model 0.00 0.00 0.06 0.31 <0.001 
 (Reference) (-0.12,0.13) (-0.07,0.19) (0.16,0.46)  
HOMA-IR, log -0.01 0.02 0.13 0.31  
Basic model 0.00 -0.03 0.01 0.12 <0.001 
 (Reference) (-0.08,0.02) (-0.04,0.07) (0.06,0.18)  
Full model * 0.00 -0.06 -0.05 0.00 0.21 
 (Reference) (-0.10,-0.01) (-0.10,-0.01) (-0.06,0.05)  
Hemoglobin A1c, % 5.31 5.38 5.44 5.46  
Basic model 0.00 0.04 0.07 0.07 0.007 
 (Reference) (0.01,0.07) (0.04,0.10) (0.03,0.10)  
Full model 0.00 0.05 0.07 0.06 0.04 
 (Reference) (0.01,0.08) (0.04,0.10) (0.02,0.09)  
Bold lines are unadjusted means. Differences are estimated from linear regression models 
with adjustment for age, sex, smoking status, and LDL-cholesterol (basic model), and 
additionally for HOMA-IR (log), body mass index, and waist circumference (full model). 
* In these regressions the outcome variable was excluded from the adjustment variables. 
Mean hemoglobin A1c were 34.6, 35.2, 35.9, and 36.1 mmol/mol for quartiles 1st to 4th of ox-
LDL respectively. The differences expressed in mmol/mol were approximately 10 times the 
figures in the table.  
Table 3. Percentages and adjusted odds ratios (95% confidence interval) for metabolic 
syndrome and its related components for comparison of the three highest ox-LDL quartiles 
with the first quartile  
 
 Quartiles of ox-LDL, U/L  
 [lowest,39.9] (39.9,49.4] (49.4,60.8] (60.8,highest] p trend 
N 997 997 996 997  
Average ox-LDL 33.06 44.72 54.69 74.64  
High waist circumference 13.7 17.4 21.4 30.2  
Basic model 1.00 1.21 1.48 2.24 <0.001 
 (Reference) (0.95,1.55) (1.15,1.90) (1.71,2.93)  
Full model * 1.00 1.04 1.23 1.70 0.008 
 (Reference) (0.71,1.54) (0.84,1.81) (1.13,2.55)  
High triglycerides 3.7 5.5 9.0 24.5  
Basic model 1.00 1.39 2.12 6.38 <0.001 
 (Reference) (0.90,2.16) (1.41,3.23) (4.30,9.66)  
Full model 1.00 1.52 2.08 5.83 <0.001 
 (Reference) (0.98,2.40) (1.37,3.21) (3.89,8.92)  
Low HDL-cholesterol 26.9 31.3 31.9 39.6  
Basic model 1.00 1.28 1.33 1.94 <0.001 
 (Reference) (1.05,1.56) (1.08,1.64) (1.55,2.44)  
Full model 1.00 1.30 1.26 1.66 0.001 
 (Reference) (1.06,1.60) (1.01,1.56) (1.31,2.11)  
High blood pressure 13.4 14.7 21.8 27.9  
Basic model 1.00 0.95 1.44 1.82 <0.001 
 (Reference) (0.73,1.24) (1.11,1.87) (1.38,2.41)  
Full model 1.00 0.93 1.33 1.47 0.002 
 (Reference) (0.71,1.23) (1.02,1.75) (1.10,1.96)  
High fasting glucose 8.3 9.2 12.7 17.5  
Basic model 1.00 0.89 1.06 1.27 0.006 
 (Reference) (0.64,1.23) (0.77,1.46) (0.91,1.77)  
Full model 1.00 0.95 0.97 0.90 0.88 
 (Reference) (0.67,1.35) (0.69,1.38) (0.63,1.29)  
Metabolic syndrome 5.4 5.1 9.8 19.1  
Basic model 1.00 0.83 1.61 3.36 <0.001 
 (Reference) (0.56,1.25) (1.12,2.34) (2.33,4.91)  
Full model 1.00 0.84 1.47 2.57 <0.001 
 (Reference) (0.52,1.36) (0.95,2.32) (1.66,4.04)  
Insulin resistance 4.7 5.2 8.1 14.8  
Basic model 1.00 0.95 1.36 2.32 <0.001 
 (Reference) (0.63,1.44) (0.92,2.02) (1.57,3.47)  
Full model * 1.00 0.89 1.10 1.65 <0.001 
 (Reference) (0.56,1.39) (0.72,1.70) (1.08,2.56)  
2-or-more non-waist criteria 10.3 11.1 18.6 31.2  
Basic model 1.00 0.95 1.59 2.95 <0.001 
 (Reference) (0.71,1.27) (1.20,2.11) (2.21,3.96)  
Full model 1.00 0.97 1.51 2.42 <0.001 
 (Reference) (0.70,1.34) (1.11,2.07) (1.76,3.34)  
3-or-more non-waist criteria 1.6 2.2 4.4 10.5  
Basic model 1.00 1.26 2.51 6.32 <0.001 
 (Reference) (0.65,2.47) (1.39,4.73) (3.57,11.82)  
Full model 1.00 1.52 2.55 5.27 <0.001 
 (Reference) (0.76,3.13) (1.36,4.99) (2.88,10.20)  
Bold lines are unadjusted proportions. Odd ratios are estimated from logistic regression 
models with adjustment for age, sex, smoking status, and LDL-cholesterol (basic model), and 
additionally for HOMA-IR (log), body mass index and waist circumference (full model). 
* In these regressions the variable used in the direct definition of the outcome variable (waist 
circumference or HOMA-IR) was excluded from the adjustment variables. 
  
Table 4. Ox-LDL-mediated fraction of the effect of waist circumference on metabolic 
syndrome-related parameters 
 
Outcome (per cm of waist) Total Direct Mediated Mediated % 
Body mass index, kg/m2 0.3163 0.3172 -0.0009 - 
 (0.3094,0.3234) (0.3104,0.3243) (-0.0017,-0.0001)  
 p<0.001 p<0.001 p=0.02  
Triglycerides, mg/dL 1.3557 1.1671 0.1886 13.9% 
 (1.1851,1.5279) (0.9944,1.3415) (0.1358,0.2497) (10.1,18.5)% 
 p<0.001 p<0.001 p<0.001 p<0.001 
HDL-cholesterol, mg/dL -0.3364 -0.3276 -0.0088 2.6% 
 (-0.3714,-0.3023) (-0.3623,-0.2921) (-0.0139,-0.0042) (1.2,4.2)% 
 p<0.001 p<0.001 p<0.001 p<0.001 
Total cholesterol, mg/dL -0.0648 -0.0938 0.0290 - 
 (-0.1042,-0.0210) (-0.1334,-0.0480) (0.0193,0.0394)  
 p=0.006 p<0.001 p<0.001  
Systolic BP, mmHg 0.3233 0.3143 0.0091 2.8% 
 (0.2876,0.3595) (0.2771,0.3515) (0.0041,0.0147) (1.3,4.6)% 
 p<0.001 p<0.001 p<0.001 p<0.001 
Diastolic BP, mmHg 0.3410 0.3352 0.0058 1.7% 
 (0.3122,0.3702) (0.3058,0.3657) (0.0020,0.0095) (0.6,2.8)% 
 p<0.001 p<0.001 p<0.001 p<0.001 
Fasting glucose, mg/dL 0.2540 0.2551 -0.0011 - 
 (0.2281,0.2788) (0.2286,0.2798) (-0.0047,0.0025)  
 p<0.001 p<0.001 p=0.52  
Insulin, pmol/L 0.1946 0.1923 0.0023 1.2% 
 (0.1834,0.2075) (0.1808,0.2051) (0.0007,0.0040) (0.4,2.1)% 
 p<0.001 p<0.001 p=0.008 p=0.008 
HOMA-IR, log 0.0329 0.0328 0.0001 0.3% 
 (0.0312,0.0346) (0.0311,0.0344) (-0.0001,0.0003) (-0.3,1.0)% 
 p<0.001 p<0.001 p=0.29 p=0.29 
Hemoglobin A1c, % 0.0031 0.0029 0.0002 5.3% 
 (0.0018,0.0042) (0.0016,0.0041) (0.0000,0.0003) (-0.1,13.7)% 
 p<0.001 p<0.001 p=0.05 p=0.05 
BP: Blood pressure. 
The columns show the total effect, direct effect, and ox-LDL-mediated effect of waist 
circumference on each metabolic syndrome-related parameter, and the proportion of the total 
effect of waist circumference that is mediated by ox-LDL. Figures in parentheses show the 
95% confidence interval calculated by nonparametric bootstrapping. The basic adjustment 
model was used (age, sex, smoking status, and LDL-cholesterol). 
 
 
 
